Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02616029 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I
A Phase 3 study of HIV-1-infection, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 66
- Enrollment target
- 20
- Study locations
NCT02616029 is a Phase 3 study of HIV-1-infection that has completed, run by Gilead Sciences. The registered enrollment target is 66 participants, below the 350-participant average among 71 other HIV-1-infection trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 2 states.
The verdict
NCT02616029, a Phase 3 study of HIV-1-infection, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 66 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) after switching from a stable regimen consisting of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) or abacavir/lamivudine (ABC/3TC) plus a third antiretroviral (ARV) agent in participants harboring the archived nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) resistance mutation M184V and/or M184I in human immunodeficiency virus (HIV) -1 reverse transcriptase. This is a two part study. If the rate of virologic failure in Part 1 is deemed acceptable, once the internal data monitoring committee officially completes the interim review, the study will continue to Part 2.
Conditions Studied
Interventions
- DRUG E/C/F/TAF
Study Locations (20)
Other
- Hopital Sainte Marguerite - Hospital - Marseille
- CHU de Nantes - Nantes
- CHU de Nice-l Archet - Nice
- CHR Orleans la Source - Orléans
- Hopital Saint Louis - Paris
- Hopital Necker les Enfants Malades - Paris
- CHU Tours Service de Médecine Internes et Maladies Infectieuses - Tours
- Universitatsklinikum Essen - Essen
- ICH Study Center- Dedicated Research - Hamburg
- Universitat Mainz - Mainz
- IRCCS A.O.U. San Martino - Genova
- Fondazione IRCCS San Raffaele del Monte Tabor - Milan
- ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco - Milan
- Comprensorio Amedeo Di Savoia Birago Di Vische - Torino
- Hospital Universitari Germans Trias i Pujol - Badalona
- Hospital Clinic de Barcelona - Hospital - Barcelona
- Hospital Universitario 12 de Octubre - Hospital - Madrid
Florida
- Midway Immunology & Research Center, LLC - Ft. Pierce
- Orlando Immunology Center - Orlando
- Triple O Research Institute PA - West Palm Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2015-12-17 |
| Est. Completion | 2019-07-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02616029
The ClinicalTrials.gov registry entry for NCT02616029 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 350-participant average among 71 other HIV-1-infection trials with a reported enrollment target (81% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV-1-infection appearing as the primary indexed condition, and to 1 intervention - of which E/C/F/TAF is the first listed.
NCT02616029 reports 20 study locations spanning 2 distinct geographic areas - top geographies include Other, Florida.
Frequently Asked Questions
What is clinical trial NCT02616029 about?
NCT02616029 is a clinical study titled "Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I". The primary objective of the study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) after switching from a stable regimen consisting of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) or abacavir/lamivudine (ABC...
What is the current status of trial NCT02616029?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 66 participants. The study started on 2015-12-17. Estimated completion is 2019-07-11.
What conditions does trial NCT02616029 study?
This clinical trial studies the following conditions: HIV-1-infection.
What interventions are being tested in trial NCT02616029?
The interventions under investigation include: E/C/F/TAF (DRUG).
Who is sponsoring clinical trial NCT02616029?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02616029 being conducted?
This trial has 20 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV-1-infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy
ACTIVE NOT RECRUITING · Phase 3
-
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
ACTIVE NOT RECRUITING · Phase 3
-
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)
ACTIVE NOT RECRUITING · Phase 3
-
DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)
ACTIVE NOT RECRUITING · Phase 3
-
Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)
ACTIVE NOT RECRUITING · Phase 3
-
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.